DORIAN GRAY project investigates the link between cardiovascular disease (CVD) and Mild Cognitive Impairment (MCI) in the ageing population. Its goal is to uncover underlying mechanisms to promote healthy, independent, and active living while reducing disease burden. Aligned with Horizon Europe’s Strategic Plan on NCDs prevention, the project focuses on two core objectives: designing a multidomain intervention to delay CVD-related MCI progression and developing digital solutions to enhance its adherence. By leveraging large datasets that include omics, brain imaging, lifestyle behaviors, and socio-economic data, the project aims to develop a trustworthy AI tool for predicting MCI. The AI tool will be upgraded into a state-of-the-art framework for modelling and simulation (digital twin), integrating real-world data collected in clinical studies from smartwatches and mobile devices. Including these digital biomarkers enable the early detection of disease and enhance precision in healthcare. The DIGITAL TWIN will inform and update a personalized multidomain intervention using a novel avatar-based coaching exergame, which will serve dual purposes: as a cognitive enhancement tool with structured physical-cognitive tasks and as a lifestyle intervention promoting positive behaviours experienced in the virtual environment. Feasibility will be tested in a pilot randomized controlled trials involving patients with MCI and heart failure, and in an implementation study with patients having MCI and cardiovascular risk factors. To achieve his aim DORIAN GRAY brings together a diverse team of experts, including clinicians, psychologists, sports scientists, computers engineers, AI specialists, stakeholders, entrepreneurs, and academics in ethics, law, and theoretical philosophy. Patients and citizens actively engage in shaping and guiding project decisions. DORIAN GRAY is projected to prevent up to 2 million dementia cases over 27 years, leading to a cost reduction of 485 billion.

Due to population ageing and advances in medical science, people with chronic diseases –including advanced severe life-threatening chronic diseases- live longer. Challenges are how to sustain quality independent living for the patient; support caregivers facing an increasing burden; create sustainable healthcare and social care systems with limited resources. ADLIFE aims to provide a solution for the integration of therapies and approaches targeting early detection and assessment of deterioration, advanced and well-coordinated care planning and integrated supportive care to enhance quality of life, reduce suffering and accelerate recovery for these patients and their families. It will deploy developed and validated personalised digital solutions for integrated supportive care based on H2020 projects C3-Cloud and Power2DM, previously tested in two health systems. The ADLIFE Toolbox solutions include: a Personalised Care Plan Management Platform, Clinical Decision Support Services; Interoperability Solutions and Patient Empowerment Platform with Just-In Time Adaptive Intervention Delivery Engine. The ADLIFE system will be deployed through large-scale pilots in 7 countries and Health Systems, involve 577 healthcare professionals from 75 hospitals, clinics and primary care services. It will prove that intelligent, collaborative digital solutions can enable care teams, patients and caregivers to improve or better maintain health in patients with advanced chronic disease (over 200,000 in the participating regions). It will test its effectiveness in 882 patients and 1243 caregivers. ADLIFE will demonstrate significant outcomes-based efficiency gains in health and care delivery enhancing seamless care coordination, avoiding gaps and overlaps in care. The ADLIFE ICT Toolbox and the evidence behind this digitally-enabled approach from the 7 reference sites will be strongly disseminated to multiple stakeholders and decision makers in Europe both online and in-person actions

CAREPATH proposes an ICT-based solution for the optimization of clinical practice in the treatment and management of multimorbid patients with Mild Cognitive Impairment or mild dementia. Such solution is targeting a more complex multimorbidity scenario and follows an integrated patient-centered approach, in order to develop a flexible and modular system to deliver a best care, adapted framework for increasing the independence and Quality of Life (QoL) of multimorbid patients with dementia. The proposed solution exploits the IONIS, C3-Cloud and imergo®-ICP healthcare platforms (whose three coordinators belong to the CAREPATH consortium) and provides a holistic environment for both healthcare providers and patients, efficiently addressing the joint multimorbidity and dementia challenges. To demonstrate and validate its results, CAREPATH will focus on combining multimorbid conditions, in different levels of complexity, and in combination with dementia. As such, CAREPATH will consider conditions such as Diabetes, Hypertension, Heart failure, Atrial Fibrillation, Chronic Obstructive Pulmonary Disease, Asthma, or Chronic Kidney Disease. The CAREPATH pilots will take place in four European countries (Spain, Romania, Germany and UK) with diverse health and social care systems, ICT landscape/digital maturity of healthcare provision and dementia national programs. The pilots will strengthen the evidence base on associated health outcomes and efficiency gains. CAREPATH will also elaborate on a methodology for computer interpretable clinical guidelines and computationally derived best clinical practice for the improved management of elderly multimorbid patients with dementia. It will develop Quality Key Performance Indicators for such a guideline-driven clinical practice and patient-centered integrated care delivery. In addition, the relevant health economic impacts of the solution, in terms of cost effectiveness and care provision inequalities will be assessed.